ArticleScientific reports2025
Heart rate management using ivabradine in acute myocardial infarction: a propensity score-matched single-center study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The therapeutic role of ivabradine in acute myocardial infarction (AMI) remains clinically debated. This study used real-world data to evaluate the rehospitalization risk associated with ivabradine treatment for heart rate control. Among 408 patients with AMI, 76 (18.6%) received ivabradine. Kaplan-Meier analysis, log-rank test, Cox proportional hazards models, and propensity score matching (PSM) were used to assess the rehospitalization risk. Additionally, an interaction test evaluated ivabradine's impact on the rehospitalization risk across relevant risk factors. Multiple imputation was employed to handle missing data. Multivariable Cox regression analysis revealed that ivabradine therapy was associated with a reduced risk of all-cause rehospitalization in patients with AMI before PSM (HR: 0.64; 95% CI: 0.44-0.91, P = 0.015), but not after (HR: 0.79; 95% CI: 0.50-1.24, P = 0.310). Subgroup analysis demonstrated a decreased rehospitalization risk following ivabradine therapy in females (HR: 0.44; 95% CI: 0.22-0.89, P = 0.023), and patients with heart rate > 70 bpm (HR: 0.59; 95% CI: 0.40-0.89, P = 0.011), Killip classification > 1 (HR: 0.62; 95% CI: 0.39-0.99, P = 0.046), anterior wall myocardial infarction (HR: 0.49; 95% CI: 0.26-0.93, P = 0.029), > 1 diseased vessel (HR: 0.59; 95% CI: 0.38-0.93, P = 0.023), and no chronic kidney disease (CKD) (HR: 0.67; 95% CI: 0.46-0.98, P = 0.040) or clopidogrel therapy (HR: 0.54; 95% CI: 0.32-0.90, P = 0.019). Target-range heart rate at first discharge was linked to a lower rehospitalization risk (HR: 0.74; 95% CI: 0.57-0.96, P = 0.025). Multivariable analysis indicated that ivabradine reduced the rehospitalization risk over a 12-month follow-up (adjusted HR: 0.80; 95% CI: 0.66-0.96, P = 0.017). In conclusion, ivabradine therapy during hospitalization was associated with a lower risk of all-cause rehospitalization in patients with AMI. However, the robustness of our findings requires further validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.